← Oncology Approval Tracker

FDA DECISION ·

Ojemda

tovorafenib · Day One Biopharmaceuticals

Accelerated approvalNew therapyPediatric low-grade glioma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Patients aged 6 months and older with relapsed or refractory pediatric low-grade glioma and a BRAF fusion, rearrangement or V600 mutation.

LAMPGEN ANALYSIS

Why it matters

The type II RAF inhibitor reaches pediatric gliomas with qualifying fusions as well as V600 variants.

What research teams should watch

Capture the precise BRAF alteration and prior therapy; use age-appropriate administration training and consistent MRI assessments.

PRIMARY RECORDS

Sources